(Total Views: 583)
Posted On: 09/05/2024 12:24:57 AM
Post# of 155843
Re: Nt2innvovate #146127
There is tons of research being done on CCR5. Mainly scholarly articles in PUBmed, the popular press not so much. I even came across a reference to CCR5 as a "Celebrity Chemokine," imagine that!
One article from 2018 is titled "The Expanding Therapeutic Perspective of CCR5 Blockade." In the intro they state:
“Over time, CCR5 has witnessed an impressive transition from being considered rather unimportant in physiology and pathology to becoming central in a growing number of pathophysiological conditions. It now turns out that the massive efforts devoted to combat HIV-1 entry by interfering with CCR5, and the subsequent production of chemokine ligand variants, small chemical compounds, and other molecular entities and strategies, may set the therapeutic standards for a wealth of different pathologies."
The fact that leronlimab isn't a "Celebrity Mab' has more to do with the previous management than a lack of interest in the academic world. And perhaps the nefarious influence of Gilead and/or other BIG Pharma that is aware of the threat LL poses to their bottom line. I was happy to hear Dr Lalezari emphasize getting articles on LL in legit publications and journals. The new trials, both pre-clinical and human, will get written up and I'm hoping will get a great deal of attention. Especially if LL can extend overall survival in MSS metastatic colorectal cancer!
https://www.frontiersin.org/journals/immunolo...01981/full
One article from 2018 is titled "The Expanding Therapeutic Perspective of CCR5 Blockade." In the intro they state:
“Over time, CCR5 has witnessed an impressive transition from being considered rather unimportant in physiology and pathology to becoming central in a growing number of pathophysiological conditions. It now turns out that the massive efforts devoted to combat HIV-1 entry by interfering with CCR5, and the subsequent production of chemokine ligand variants, small chemical compounds, and other molecular entities and strategies, may set the therapeutic standards for a wealth of different pathologies."
The fact that leronlimab isn't a "Celebrity Mab' has more to do with the previous management than a lack of interest in the academic world. And perhaps the nefarious influence of Gilead and/or other BIG Pharma that is aware of the threat LL poses to their bottom line. I was happy to hear Dr Lalezari emphasize getting articles on LL in legit publications and journals. The new trials, both pre-clinical and human, will get written up and I'm hoping will get a great deal of attention. Especially if LL can extend overall survival in MSS metastatic colorectal cancer!
https://www.frontiersin.org/journals/immunolo...01981/full
(7)
(0)
